

## 30 Day Change Notice Effective Date: July 1, 2023

NEW NON PREFERRED DRUGS		
THERAPEUTIC CLASS	PA REQUIRED NON PREFERRED	
Blood Formation, Coagulation, and Thrombosis	Rolvedon	
Agents: Colony Stimulating Factors	Stimufend	
Central Nervous System (CNS) Agents: Attention	Xelstrym	
Deficit Hyperactivity Disorder Agents		
Central Nervous System (CNS) Agents: Multiple	Tascenso ODT	
Sclerosis*		
Endocrine Agents: Diabetes – Insulin	Humalog U-100 Tempo Pen	
	Basaglar Tempo Pen	
	Lyumjev Tempo Pen	
Topical Agents: Immunomodulators	Hyftor	

"Non Preferred, PA required" to "Preferred, Clinical PA required"	
THERAPEUTIC CLASS	
Blood Formation, Coagulation, and Thrombosis	Kovaltry
Agents: Hemophilia Factor*	

THERAPEUTIC CATEGORIES WITH CHANGES IN CRITERIA	
Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents	
Endocrine Agents: Diabetes – Insulin	
Central Nervous System (CNS) Agents: Antidepressants*	
Central Nervous System (CNS) Agents: Atypical Antipsychotics*	
Central Nervous System (CNS) Agents: Anticonvulsants*	
Central Nervous System (CNS) Agents: Anti-Migraine Agents, Cluster Headache	

REVISED THERAPEUTIC CATEGORY CRITERIA		
THERAPEUTIC	SUMMARY OF CHANGE	
CLASS	SOMMAN OF CHANGE	
Central Nervous	Add AR to Xelstrym (PA for less than 6 years)	
System (CNS)		
Agents: Attention		
Deficit		
Hyperactivity		
Disorder Agents		
Endocrine Agents:	ADDITIONAL TEMPO PEN CRITERIA	
Diabetes – Insulin	<ul> <li>Must have had an inadequate clinical response or documentation</li> </ul>	
	of medical necessity beyond convenience for why the patient	
	cannot use the corresponding FlexPens or Kwikpens	

Date of Notice: 6/1/2023



## 30 Day Change Notice Effective Date: July 1, 2023

ı	Encouve Date: Gary 1, 2020
Central Nervous	
System (CNS)	ADDITIONAL DEXTROMETHORPHAN/BUPROPION (AUVELITY) CRITERIA
Agents:	<ul> <li>Must provide documentation for patient's inability to use the individual</li> </ul>
Antidepressants*	<mark>drugs</mark>
Antiacpicssants	<ul> <li>Must have an inadequate clinical response of at least 30 days with ALL</li> </ul>
	of the following:
	<ul> <li>ONE dopamine/norepinephrine reuptake inhibitor (DNRI)</li> </ul>
	<ul> <li>ONE selective norepinephrine reuptake inhibitor (SNRI)</li> </ul>
	O ONE tricyclic antidepressant (TCA)
	<ul> <li>TWO selective serotonin reuptake inhibitors (SSRIs) (ONE of</li> </ul>
	which must be either vilazodone (Viibryd) OR vortioxetine
	(Trintellix)
	PSYCHIATRIST EXEMPTION:
	Prescribers (as identified below) are exempt from prior authorization of any non-
	preferred antidepressant, or step therapy of any preferred branddrug, in the
	standard tablet/capsule dosage forms. Other dosage forms may still require prior
	authorization. The exemption will be processed by the claims system
	when the pharmacy has submitted the prescriber on the claim using the individual
	national provider identifier (NPI) for the prescriber.
	Prescribers are defined as:
	<b>FFS:</b> Physicians who are registered with Ohio Medicaid as having a specialty in
	psychiatry.
	MCOs: Physicians with a specialty in psychiatry, nurse practitioners certified in
	psychiatric mental health, or clinical nurse specialists certified in psychiatric ment
	health, who are credentialed via with the Ohio Department of Medicaid managed
	<del>care plan</del> .
Central Nervous	PSYCHIATRIST EXEMPTION:
System (CNS)	Prescribers (as identified below) are exempt from prior authorization of any non-
Agents: Atypical	preferred second-generation antipsychotic, or step therapy of any preferred
Antipsychotics*	branddrug, in the standard tablet/capsule and long-acting injectable dosage
	forms. Other dosage forms may still require prior authorization. The exemption
	will be processed by the claims system when the pharmacy has submitted the
	prescriber on the claim using the individual national provider identifier (NPI) for
	the prescriber
	Prescribers are defined as:
	FFS: Physicians who are registered with Ohio Medicaid as having a specialty in
	psychiatry.
	MCOs: Physicians with a specialty in psychiatry, nurse practitioners certified in
	psychiatric mental health, or clinical nurse specialists certified in psychiatric
	mental health, who are credentialed via with the Ohio Department of Medicaid
Control Norman	managed care plan.
Central Nervous	NEUROLOGIST EXEMPTION:  Dracerintings submitted from a prescriber who is registered exedentialed as a
System (CNS)	Prescriptions submitted from a prescriber who is registered redentialed as a

Date of Notice: 6/1/2023



## 30 Day Change Notice Effective Date: July 1, 2023

l l	=1100ti10
Agents:	neurology specialty with Ohio Medicaid AND for drugs that are used only for
Anticonvulsants*	seizures, there must have been an inadequate clinical response of at least 30
	days with one preferred drug. This provision applies only to the standard
	tablet/capsule dosage form and does not apply to brand products with available
	<del>generic alternatives</del> .
Central Nervous	QL – Emgality: 3 doses per 30 days (for initial loading dose only), then 1 dose per
System (CNS)	30 days thereafter
Agents: Anti-	
Migraine Agents,	
Cluster Headache	

OH-MED-M-2308985

Date of Notice: 6/1/2023